Treat Primary and Metastatic Liver Tumors

Metastatic Cancer Clinical Trial

Official title: Radioembolization to Treat Primary and Metastatic Liver Tumors

Status Enrolling by invitation

Clinical Trial Summary

The use of Radiospheres in the management of intrahepatic cholangiocarcinoma is largely unknown and not reported in the medical literature. Methodist Dallas Medical Center has a large volume of IR procedures with Radioembolization and the investigators feel it is imperative to understand the outcomes, risks and benefits of the therapy in order to formulate recommendation to other centers.

Clinical Trial Description

A retrospective chart review of patients who have the diagnosis of intrahepatic cholangiocarcinoma. Only patients treated at MDMC are included and data will be obtained from Meditech and Epic. A non-identified database of cases with the diagnosis of intrahepatic cholangiocarcinoma already treated with radiospheres will be created and compared with cases treated by other means. Intrahepatic cholangiocarcinoma is the second most common primary malignancy of the liver. The standard therapy has been resection but many cases are not resectable due to comorbidities or other poor surgical candidacy factors. Most of these patients end up getting chemotherapy which can be toxic and sometimes poorly tolerated. Intrarterial glass or resin radioembolization has been used and published from only 3 centers in the medical literature and it has been shown to be a reasonable alternative to the above options. At MDMC, this therapy has been used effectively and it is important to describe the investigator's experience. ;

Related Conditions & MeSH terms

• Cholangiocarcinoma
• Intrahepatic Cholangiocarcinoma
• Liver Neoplasms
• Liver Tumor
• Metastatic Cancer
• Metastatic Liver Cancer

• NCT number: NCT05240040
• Study type: Observational
• Source: Methodist Health System
• Status: Enrolling by invitation
• Start date: April 26, 2016
• Completion date: May 2022